DarioHealth (NASDAQ:DRIO) Stock Passes Below 200-Day Moving Average – Should You Sell?

DarioHealth Corp. (NASDAQ:DRIO)’s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.22 and traded as low as $1.02. DarioHealth shares last traded at $1.06, with a volume of 84,911 shares traded.

DarioHealth Price Performance

The company has a market cap of $31.57 million, a price-to-earnings ratio of -0.63 and a beta of 1.48. The stock has a 50 day simple moving average of $0.92 and a two-hundred day simple moving average of $1.22. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.26 and a quick ratio of 1.96.

DarioHealth (NASDAQ:DRIO) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.43. DarioHealth had a negative net margin of 265.33% and a negative return on equity of 74.64%. The firm had revenue of $6.26 million for the quarter, compared to analysts’ expectations of $7.57 million. On average, equities research analysts predict that DarioHealth Corp. will post -1.21 earnings per share for the current fiscal year.

Institutional Trading of DarioHealth

An institutional investor recently raised its position in DarioHealth stock. Appian Way Asset Management LP increased its holdings in DarioHealth Corp. (NASDAQ:DRIO) by 0.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,334,142 shares of the company’s stock after acquiring an additional 11,698 shares during the period. DarioHealth makes up about 0.5% of Appian Way Asset Management LP’s holdings, making the stock its 23rd largest holding. Appian Way Asset Management LP owned approximately 4.50% of DarioHealth worth $2,041,000 as of its most recent SEC filing. 33.39% of the stock is currently owned by institutional investors and hedge funds.

DarioHealth Company Profile

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.